Status:
COMPLETED
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate p...
Eligibility Criteria
Inclusion
- hyperlipidemia
- urinary protein
- diabetes
Exclusion
- previous rosuvastatin treatment \< 6 months prior to Visit 1
- statin intolerance
- severe hypertension
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
353 Patients enrolled
Trial Details
Trial ID
NCT00296374
Start Date
February 1 2006
End Date
March 1 2009
Last Update
September 1 2011
Active Locations (116)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Avondale, Arizona, United States
2
Research Site
Phoenix, Arizona, United States
3
Research Site
Jonesboro, Arkansas, United States
4
Research Site
Pasadena, California, United States